BALCHEM CORPORATION. Q Investor Relations Presentation

Size: px
Start display at page:

Download "BALCHEM CORPORATION. Q Investor Relations Presentation"

Transcription

1 BALCHEM CORPORATION Q Investor Relations Presentation

2 Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life on the planet. Highlights NASDAQ: BCPC Founded in 1967 Headquarters: New Hampton, NY Approximately 1,100 Employees 18 Manufacturing Sites: - 17 in North America - 1 in Europe 5 Technology Centers 2017 Revenues of $595M 2017 Adj. EBITDA of $148M or 24.9% of sales 2017 Cash Flow From Operations $111M 2

3 Key Investment Highlights Leading Positions in Attractive Growth Markets Creating New Demand Through Innovation Delivering Healthy Margins Generating Cash Flow from Operations Available for Reinvestment Led by a Strong, Experienced Management Team 3

4 Balchem at a Glance HUMAN NUTRITION & HEALTH ANIMAL NUTRITION & HEALTH Markets Served Solutions Markets Served Solutions Food and Beverage Supplements Infant & Toddler Formula Organic Cereal Micro-encapsulation Choline Chelated Minerals Powder, Flavor, & Cereal Systems HUMAN NUTRITION 53% ANIMAL NUTRITION 27% Dairy Poultry Companion Animal Swine Aquaculture Micro-encapsulation Choline Chelated Minerals Amino Acids and Other Ruminant Nutrients SPECIALTY PRODUCTS Markets Served Medical Device Sterilization Nut and spice fumigation Plant Nutrition Solutions Chelated Minerals Ethylene Oxide Propylene Oxide SPECIALTY PRODUCTS 12% INDUSTRIAL PRODUCTS 8% INDUSTRIAL PRODUCTS Markets Served Oil & Gas Fracking Electronics Fertilizer Solutions Micro-encapsulation Choline Choline Derivatives 4

5 2016 Acquisition of Albion Minerals Balchem acquired Albion International in February 2016 Highlights Synergistic with our Human Nutrition and Health segment, delivering customized food and beverage ingredient systems, and essential nutrients through the food, supplement and pharmaceutical marketplace. Facilitates growth and technological advancement of Balchem s existing Animal Nutrition & Health chelated mineral business. A premium brand with high margins providing high quality ingredients that are built on strong science and innovative technologies, and is recognized worldwide for their quality, efficacy and safety. Expands geographic footprint to create a strong position as a technological leader in human health and wellness solutions. Human Nutrition Key products include: Magnesium Iron Calcium Zinc Ferrochel Creatine MagnaPower Plant Nutrition Key products include: Multi-element Calcium Zinc Potassium & Magnesium Metalosate Revenue 34% Human Nutrition 66% Plant Nutrition 5

6 2017 Acquisitions of Chol-Mix and IFP Balchem acquired Chol-Mix Kft. in March 2017 Highlights Synergistic with our Animal Nutrition and Health segment, marketing and manufacturing Dry Choline Chloride. Animal Nutrition Key products include: Dry Choline Chloride Provides increased Dry Choline capacity at a manufacturing site in Europe. Expands geographic footprint to create stronger position in Eastern Europe. Balchem acquired Innovative Food Processors (IFP) in June 2017 Highlights Synergistic with our Human Nutrition and Health segment, marketing and manufacturing agglomerated and micro-encapsulated food and nutritional ingredients. Enhances processing technology through added agglomeration and micro-encapsulation assets and technological know-how. Ingredient Solutions Key technologies and products include: Micro-encapsulation Agglomeration Contract Packaging Food and Nutritional Powder Systems Expands market reach with new customer acquisition and broadening of innovative and value-added food, beverage, and nutrient systems. 6

7 Five Year Financial Performance FY 2017 FY 2012 CAGR Revenue % Gross Margin % As a % of Sales 31.8% 28.8% Operating Income % Net Earnings % Earnings Per Share % Adjusted EBITDA % As a % of Sales 24.9% 23.6% Adjusted Earnings Per Share % Note: Dollars in Millions, except percent and per share data Adjusted EBITDA is defined as EBITDA plus Stock Based Compensation, transaction and integration costs, and FV of inventory adjustment. Adjusted earnings per share is defined as GAAP net earnings plus the tax adjusted FV of inventory expense, amortization of intangible assets, transaction and integration costs, excluding the impact of ASU and excluding the impact of Tax Cuts and Jobs Act 7

8 Key Financial Metrics $700 $600 $500 $400 $300 $200 $100 $ Revenue ($M) $100 $90 $80 $70 $60 $50 $40 $30 $20 $10 $0 Net Income ($M) * $3.00 $2.50 $2.00 $1.50 $1.00 $0.50 $ Earnings Per Share * $120 $100 $80 $60 $40 $20 $0 Cash From Operations ($M) * Excludes one-time impact from Tax Cuts and Jobs Act, see appendix for reconciliation of Net Income and Earnings per share 8

9 Full Year 2017 Financial Performance FY 2017 FY 2016 Change Revenue % Gross Margin % As a % of Sales 31.8% 32.7% Operating Income % Net Earnings % Earnings Per Share % Adjusted EBITDA % As a % of Sales 24.9% 27.0% Adjusted Earnings Per Share % Note: Dollars in Millions, except percent and per share data Adjusted EBITDA is defined as EBITDA plus Stock Based Compensation, transaction and integration costs, and FV of inventory adjustment. Adjusted earnings per share is defined as GAAP net earnings plus the tax adjusted FV of inventory expense, amortization of intangible assets, transaction and integration costs, excluding the impact of ASU and excluding the impact of Tax Cuts and Jobs Act 9

10 Q Financial Performance Q Q Change Revenue % Gross Margin % As a % of Sales 32.4% 33.3% Operating Income % Net Earnings % Earnings Per Share % Adjusted EBITDA % As a % of Sales 25.1% 26.8% Adjusted Earnings Per Share % Note: Dollars in Millions, except percent and per share data Adjusted EBITDA is defined as EBITDA plus Stock Based Compensation, transaction and integration costs, and FV of inventory adjustment. Adjusted earnings per share is defined as GAAP net earnings plus the tax adjusted FV of inventory expense, amortization of intangible assets, transaction and integration costs, excluding the impact of ASU and excluding the impact of Tax Cuts and Jobs Act 10

11 HUMAN NUTRITION & HEALTH WE MAKE IT HEALTHY HUMAN NUTRITION & HEALTH WE MAKE IT HEALTHY

12 Human Nutrition & Health at a Glance HUMAN NUTRITION & HEALTH Markets Served Solutions ($M) $350 $300 $250 Revenue $297 $278 $316 Food and Beverage Supplement Infant & Toddler Formula Organic Cereal Micro-encapsulation Choline Chelated Minerals Powder, Flavor, & Cereal Systems HUMAN NUTRITION 53% $200 $150 $100 $50 $0 $206 $ ($M) $100 Adj. EBITDA $80 $60 $71 $78 $80 $40 $48 $20 $0 $

13 Human Nutrition & Health Performance Q Q FY 2017 FY 2016 Revenue ($M) $ 83.3 $ 75.9 $ $ Adjusted EBITDA ($M) $ 21.4 $ 19.3 $ 80.0 $ 77.6 Leveraging Growth Opportunities Across The Segment Expanding Choline Awareness Growth Platforms Curemark Delivery System Agglomeration Technology Clean Label Systems Human Chelated Minerals Geographic Expansion 13

14 ANIMAL NUTRITION & HEALTH BLENDING SCIENCE AND NUTRITION ANIMAL NUTRITION & HEALTH BLENDING SCIENCE AND NUTRITION

15 Animal Nutrition & Health at a Glance ($M) Revenue $200 $150 $156 $176 $166 $161 $158 ANIMAL NUTRITION & HEALTH Markets Served Solutions $100 $50 $ ANIMAL NUTRITION 27% Dairy Poultry Companion Animal Swine Aquaculture Micro-encapsulation Choline Chelated Minerals Amino Acids and Other Ruminant Nutrients ($M) $40 Adj. EBITDA $30 $30 $35 $37 $29 $20 $24 $10 $

16 Animal Nutrition & Health Performance Q Q FY 2017 FY 2016 Revenue ($M) $ 44.6 $ 42.5 $ $ Adjusted EBITDA ($M) $ 9.6 $ 10.0 $ 28.7 $ 36.6 Innovative, Science Based Nutrition for Animals Growth Platforms Companion Animal & Aquaculture Market Penetration National Research Council Recommendation on Choline Geographic Expansion BASF Collaboration for Antibiotic Free Solutions 16

17 SPECIALTY PRODUCTS WE MAKE IT GROW WE MAKE IT SAFE SPECIALTY PRODUCTS WE MAKE IT GROW / WE MAKE IT SAFE

18 Specialty Products at a Glance ($M) Revenue $72 $60 $70 $73 $48 $36 $24 $12 $51 $54 $54 $ SPECIALTY PRODUCTS Markets Served Solutions SPECIALTY PRODUCTS 12% ($M) $35 $30 Adj. EBITDA $32 $32 Medical Device Sterilization Nut and spice fumigation Plant Nutrition Chelated Minerals Ethylene Oxide Propylene Oxide $25 $20 $15 $10 $24 $25 $28 $5 $

19 Specialty Products Performance Q Q FY 2017 FY 2016 Revenue ($M) $ 16.5 $ 16.2 $ 73.4 $ 70.1 Adjusted EBITDA ($M) $ 6.8 $ 7.1 $ 31.9 $ 32.1 Growth Platforms New Applications for Pasteurization/Fumigation Geographic Expansion of Plant Nutrition Expand Plant Micronutrient Product Line & Applications 19

20 INDUSTRIAL PRODUCTS WE MAKE IT GREEN Industrial Products INDUSTRIAL PRODUCTS WE MAKE IT GREEN 20

21 Industrial Products at a Glance ($M) $125 Revenue $100 $105 $75 $50 $25 $0 ($M) $20 $18 $16 $14 $12 $10 $8 $6 $4 $2 $0 $83 $54 $48 $ Adj. EBITDA $19 $17 $7 $7 $ INDUSTRIAL PRODUCTS 8% INDUSTRIAL PRODUCTS Markets Served Oil & Gas Fracking Electronics Fertilizer Solutions Micro-encapsulation Choline Choline Derivatives 21

22 Industrial Products Performance Q Q FY 2017 FY 2016 Revenue ($M) $ 14.9 $ 6.2 $ 48.0 $ 24.8 Adjusted EBITDA ($M) $ 2.2 $ 1.3 $ 7.3 $ 2.9 Growth Platforms Green Clay Stabilization Solutions Low Cost Clay Stabilization 22

23 Looking Ahead HUMAN NUTRITION & HEALTH NUTRITION & PHARMA

24 Future Positioned For Growth in Attractive Markets Organic Growth Growth through Acquisitions Creating Demand Through Innovation Recent Acquisitions add new Technologies, International Reach, and Synergistic Opportunities Building Global Human and Animal Nutrition & Health Businesses Healthy Margin Profile, Strong Cash Flow, and Solid Balance Sheet to Execute 24

25 HUMAN NUTRITION & HEALTH CEREAL SYSTEMS At our core, we are a health and nutrition company. Ted Harris, President and CEO

26 Appendix 26

27 Reconciliation of Net Earnings and EPS For the Year Ended December 31, ($M) GAAP Net Earnings $ 90.1 Less: Impact of Tax Cuts and Jobs Act $ 24.9 Tax Cuts and Jobs Act adjusted net earnings $ 65.1 Tax Cuts and Jobs Act adjusted earnings per common share $ 2.02 Shares used in the calculations of diluted and adjusted net earnings per common share 32.2 Net Earnings are adjusted only for the impact of the Tax Cuts and Jobs Act, enacted on December 22, 2017 by the U.S. government Note: Dollars in Millions, except percent and per share data 27

Balchem Corporation Investor Relations

Balchem Corporation Investor Relations Balchem Corporation Investor Relations May 2017 Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life on the planet.

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

The acquisition of Fortitech

The acquisition of Fortitech The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale

More information

Investor Presentation

Investor Presentation Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

DuPont Nutrition & Health Craig Binetti, President

DuPont Nutrition & Health Craig Binetti, President Craig Binetti, President Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this

More information

Continued value growth

Continued value growth Continued value growth Leendert Staal CEO & President DSM Nutritional Products Capital Markets Days 2012 Safe harbor statement This presentation may contain forward-looking statements with respect to DSM

More information

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm

More information

Harm de Wildt MD TNI

Harm de Wildt MD TNI Harm de Wildt MD TNI Nutreco Capital Markets Day Derbyshire, UK 17 September 1 2013 Agenda 1 2 3 Market overview Animal Nutrition Europe Animal Nutrition strategic priorities Application Solution Centres

More information

Natus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017

Natus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Natus Medical Incorporated Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Forward-Looking Statements This presentation contains forward-looking statements including statements regarding our

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

A GLOBAL LEADER IN PERSONALIZED NUTRITION

A GLOBAL LEADER IN PERSONALIZED NUTRITION A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

NASDAQ: FHCO 2016 Annual Meeting

NASDAQ: FHCO 2016 Annual Meeting NASDAQ: FHCO 2016 Annual Meeting Q1 2016 At a Glance NASDAQ Core product FHCO FC2 Female Condom Gross margin ~66% Operating margin ~29% Total current assets $24 million no L/T debt Profitable Starting

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,

More information

For personal use only

For personal use only Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for

More information

Solvay expands its specialty polymers offerings with Ryton PPS acquisition

Solvay expands its specialty polymers offerings with Ryton PPS acquisition Solvay expands its specialty polymers offerings with Ryton PPS acquisition Sustained strategic portfolio realignment With Ryton PPS* acquisition, Solvay further strengthens unmatched leadership in Specialty

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018

Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements

More information

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012 Cepheid The MDx Growth Leader William Blair Growth Stock Conference June 12, 2012 Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements

More information

Investor Presentation. Q April 26, 2018

Investor Presentation. Q April 26, 2018 Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities

More information

Results Briefing. 15 ~ 17 May 2007

Results Briefing. 15 ~ 17 May 2007 Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights

More information

Financial Presentation

Financial Presentation Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with

More information

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

An exciting combination in a high growth, high margin Nutrition category. Name of chairman An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

Reynolds American to Acquire Lorillard

Reynolds American to Acquire Lorillard Reynolds American to Acquire Lorillard The Next Step in Transforming Tobacco July 15, 2014 Forward Looking Statements This presentation contains forward-looking information. Future results or events can

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Investor Presentation. Q October 26, 2017

Investor Presentation. Q October 26, 2017 Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private

More information

5 Reasons Why It s the #1 Ingredient Opportunity

5 Reasons Why It s the #1 Ingredient Opportunity EFSA laim ApprC oved s 5 Reasons Why It s the #1 Ingredient Opportunity 5 Reasons Why You Need The global market for supplements continues to grow, with the Nutrition Business Journal (NBJ) reporting dollar

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking

More information

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to

More information

Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016

Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International

First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International Tom Hein, CFO Safe Harbor Statement Except for historical information contained herein, the statements

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating

More information

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region Investor Day LA&C Region Lausanne, September 29, 2016 Jeanne Pollès President, Latin America & Canada Region Agenda Regional Overview and Performance Regional Strategies Key Markets Conclusion 2 LA&C Regional

More information

GELATIN & AKIOLIS. Because every bio-molecule counts. Pol Deturck EVP Chemicals & Organic Specialties

GELATIN & AKIOLIS. Because every bio-molecule counts. Pol Deturck EVP Chemicals & Organic Specialties GELATIN & AKIOLIS Because every bio-molecule counts Pol Deturck EVP Chemicals & Organic Specialties Why our bioplatform is promising Dual service provider and highly reliable partner Akiolis, the 3 rd

More information

Total Face Group Limited

Total Face Group Limited Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position

More information

Bank of America 38 th Annual Investment Conference. San Francisco, CA September 17 th, 2008

Bank of America 38 th Annual Investment Conference. San Francisco, CA September 17 th, 2008 Bank of America 38 th Annual Investment Conference 1 San Francisco, CA September 17 th, 2008 Introduction This slide presentation contains forward-looking statements which are subject to change based on

More information

Value growth in Human Nutrition & Health

Value growth in Human Nutrition & Health Value growth in Human Nutrition & Health Rick Greubel President Human Nutrition & Health US Field Trip September 4, 2014 Safe harbor statement This presentation may contain forward-looking statements with

More information

FRUIT STARCH SUGAR. AGRANA Beteiligungs-AG. The natural upgrade. Corporate presentation

FRUIT STARCH SUGAR. AGRANA Beteiligungs-AG. The natural upgrade. Corporate presentation FRUIT STARCH SUGAR The natural upgrade AGRANA Beteiligungs-AG Corporate presentation 2018 1 ABOUT US AGRANA FACTS We refine agricultural raw materials, turning them into a range of different industrial

More information

J.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009

J.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009 J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various

More information

Very good Q3 contribution from Vegetable Juices Inc.

Very good Q3 contribution from Vegetable Juices Inc. 2014 nine-month sales (1 st January to 30 September 2014) Very good Q3 contribution from Vegetable Juices Inc. Worldwide economic environment still adverse Sustained growth by Food & Beverage Press release

More information

5 Reasons Why It s the #1 Ingredient Opportunity. EFSA Claims Approved

5 Reasons Why It s the #1 Ingredient Opportunity. EFSA Claims Approved 5 Reasons Why It s the #1 Ingredient Opportunity EFSA Claims Approved 5 Reasons Why You Need The global market for supplements continues to grow, with the Nutrition Business Journal (NBJ) reporting dollar

More information

Cowen Healthcare Conference

Cowen Healthcare Conference Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT

More information

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish

More information

Putting ALK on the right growth trajectory

Putting ALK on the right growth trajectory Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large

More information

ASX Investor Presentation

ASX Investor Presentation ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION

More information

Second Quarter Results to June 30, 2010

Second Quarter Results to June 30, 2010 Second Quarter Results to June 30, 2010 Shire plc August 4, 2010 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals Sylvie

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

ADM to Acquire WILD Flavors

ADM to Acquire WILD Flavors ADM to Acquire WILD Flavors Creating a Leading Global Flavors and Specialty-Ingredients Business July 7, 2014 ARCHER DANIELS MIDLAND COMPANY 1 Safe Harbor Statement Some of our statements constitute forward-looking

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

BancAnalysts Association of Boston Conference Presentation. November 3, 2017

BancAnalysts Association of Boston Conference Presentation. November 3, 2017 BancAnalysts Association of Boston Conference Presentation November 3, 2017 Disclaimer This presentation contains forward- looking statements within the meaning of the Private Securities Litigation Reform

More information

Investor Presentation

Investor Presentation Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities

More information

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic

More information

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

CHOLINE CHLORIDE MARKET

CHOLINE CHLORIDE MARKET CHOLINE CHLORIDE MARKET BY END USER (Poultry Feed, Swine Feed, Ruminant Feed, Aqua Feed, Other Feed, Human Nutrition, and Oil & Gas) & BY GEOGRAPHY Regional Trend & Forecast to 2019 www.marketsandmarkets.com

More information

2014 CAGNY Investor Presentation. February 19, 2014

2014 CAGNY Investor Presentation. February 19, 2014 2014 CAGNY Investor Presentation February 19, 2014 Management Team Participants Howard Willard EVP and Chief Financial Officer, Altria Group, Inc. Dave Beran President and Chief Operating Officer, Altria

More information

THIRD QUARTER REPORT 2011 (UNAUDITED)

THIRD QUARTER REPORT 2011 (UNAUDITED) THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor

More information

Bank of America Merrill Lynch Global Healthcare Conference 2012

Bank of America Merrill Lynch Global Healthcare Conference 2012 Bank of America Merrill Lynch Global Healthcare Conference 2012 Shire plc September 12, 2012 Graham Hetherington Chief Financial Officer Our purpose We enable people with life-altering conditions to lead

More information

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Walgreens (WAG) Analyst: Juan Fabres Fall 2014 Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores

More information

Annual Shareholders Meeting

Annual Shareholders Meeting Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking

More information

Closing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011

Closing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011 Closing of Nucletron acquisition Building a stronger position in the cancer care market September 15, 2011 Important step in Elekta s growth strategy Nucletron is the world leader in Brachytherapy and

More information

Investor Presentation. Q May 21, 2018

Investor Presentation. Q May 21, 2018 Investor Presentation Q3 2018 May 21, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Third Quarter Results to September 30, 2009

Third Quarter Results to September 30, 2009 Third Quarter Results to September 30, 2009 Shire plc October 30, 2009 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals

More information

Driving Profitable Growth

Driving Profitable Growth Driving Profitable Growth through science-based, sustainable solutions Feike Sijbesma, CEO Royal DSM CONSUMER ANALYST GROUP EUROPE, London 22 March 2016 ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor

More information

StockPotentials January 28, 2011.

StockPotentials January 28, 2011. .......... StockPotentials January 28, 2011. NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Price (January 28, 2011) $2.08 52-Week Range $2.60-$1.02 Shares O/S Market Cap 42.04 million $87.4 million 50-day

More information

Letter to Shareholders SEMI-ANNUAL REPORT 2008

Letter to Shareholders SEMI-ANNUAL REPORT 2008 Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into

More information

MiFOOD2017. Grand Rapids April 18 th Daragh Maccabee SVP Procurement & Dairy Economics Glanbia Nutritionals

MiFOOD2017. Grand Rapids April 18 th Daragh Maccabee SVP Procurement & Dairy Economics Glanbia Nutritionals MiFOOD2017 Grand Rapids April 18 th 2017 Daragh Maccabee SVP Procurement & Dairy Economics Glanbia Nutritionals OUR BUSINESSES TODAY MARKET CAP 5BN EMPLOYEES 6,200 GLANBIA PERFORMANCE NUTRITION GLANBIA

More information

First Quarter Results to March 31, Shire plc April 25, 2008

First Quarter Results to March 31, Shire plc April 25, 2008 First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009 FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)

More information

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Investor Day EEMA Region Lausanne, September 29, 2016 Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Agenda Overview and Key Results Vision and Strategic Pillars

More information

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset

More information

FY2007 Consolidated Financial Overview

FY2007 Consolidated Financial Overview FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION JUNE 2016 OTCQB:CANN ABOUT General Cannabis Corporation (GCC) is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. We

More information

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders Contact: Investor Relations: Bob Bannon (336) 741-3359 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2016-22 RAI reports strong 2Q16 performance

More information

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant

More information

LUZHOU BIO-CHEM TECHNOLOGY LIMITED. 1HFY2006 Results Briefing. August 15, 2006

LUZHOU BIO-CHEM TECHNOLOGY LIMITED. 1HFY2006 Results Briefing. August 15, 2006 LUZHOU BIO-CHEM TECHNOLOGY LIMITED 1HFY2006 Results Briefing August 15, 2006 Agenda Who We Are A Growing Industry Financial Review Corporate Updates Future Plans Q&A 2 Who We Are Leading Corn Sweetener

More information

Fourth quarter and full year results to December 31, 2012

Fourth quarter and full year results to December 31, 2012 Fourth quarter and full year results to December 31, 2012 Shire plc February 14, 2013 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Flemming Ornskov Chief Executive

More information

Creating Value for Shareholders: Now and For the Long Term. October 2015

Creating Value for Shareholders: Now and For the Long Term. October 2015 Creating Value for Shareholders: Now and For the Long Term October 2015 1 Important Information Forward Looking Statements Certain statements in this presentation are forward-looking statements. These

More information

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011 Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee

More information

Zacks Small-Cap Research

Zacks Small-Cap Research Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,

More information

Table of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7

Table of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7 Solvay Media Kit Table of Contents 1. About Solvay 3 1.1. Solvay at a Glance 4 1.2. Group Portfolio 5 2. Transforming Solvay 6 2.1. Solvay s Portfolio Upgrade 7 3. Organizing for the Future 9 3.1. Why

More information

DSM Capital Markets Day 2018

DSM Capital Markets Day 2018 DSM Capital Markets Day 2018 Human Nutrition & Health Jeremy Xu President Human Nutrition & Health ROYAL DSM CAPITAL MARKETS DAY LONDON (UK) 20 JUNE 2018 Safe harbor statement This presentation may contain

More information

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15. [NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS

More information

Key figures (consolidated)

Key figures (consolidated) Nestlé Group 2013 Key figures (consolidated) In millions of CHF (except for data per share) 2013 Results Sales 92158 Trading operating profit 14047 as % of sales 15.2% Profit for the year attributable

More information